Log In
Print
BCIQ
Print
Print this Print this
 

AIC813

  Manage Alerts
Collapse Summary General Information
Company AiCuris GmbH & Co. KG
DescriptionHuman Cytomegalovirus (HCMV) inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationCytomegalovirus (CMV)
Indication DetailsProphylaxis and pre-emptive treatment of HVMV viremia; Treat cytomegalovirus (CMV) infections; Treat HCMV-infected HIV patients
Regulatory Designation
Partner Merck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$573.1M

$142.5M

$430.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today